KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortizatization of Intangibles: 2018-2023

Historic Amortizatization of Intangibles for Esperion Therapeutics (ESPR) over the last 4 years, with Jun 2023 value amounting to $73,000.

  • Esperion Therapeutics' Amortizatization of Intangibles rose 136.68% to $73,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $505,000, marking a year-over-year increase of 232.89%. This contributed to the annual value of $412,000 for FY2023, which is 247.67% up from last year.
  • According to the latest figures from Q2 2023, Esperion Therapeutics' Amortizatization of Intangibles is $73,000, which was down 78.47% from $339,000 recorded in Q1 2023.
  • Over the past 5 years, Esperion Therapeutics' Amortizatization of Intangibles peaked at $339,000 during Q1 2023, and registered a low of -$199,000 during Q2 2022.
  • In the last 3 years, Esperion Therapeutics' Amortizatization of Intangibles had a median value of -$12,000 in 2021 and averaged $17,286.
  • In the last 5 years, Esperion Therapeutics' Amortizatization of Intangibles tumbled by 78.95% in 2020 and then surged by 2,266.67% in 2022.
  • Esperion Therapeutics' Amortizatization of Intangibles (Quarterly) stood at $60,000 in 2019, then slumped by 78.95% to $4,000 in 2020, then reached -$12,000 in 2021, then surged by 2,266.67% to $260,000 in 2022, then surged by 136.68% to $73,000 in 2023.
  • Its Amortizatization of Intangibles was $73,000 in Q2 2023, compared to $339,000 in Q1 2023 and $260,000 in Q4 2022.